(Q53298473)

13 May 2018

title

Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. (English)

1 reference

13 May 2018

1 reference

1

1 reference

13 May 2018

Georgia Chenevix-Trench

4

object named as

Chenevix-Trench G

1 reference

13 May 2018

Bast RC

2

1 reference

13 May 2018

Berek J

3

1 reference

13 May 2018

Gore M

5

1 reference

13 May 2018

Hamilton T

6

1 reference

13 May 2018

Jacobs I

7

1 reference

13 May 2018

Mills G

8

1 reference

13 May 2018

Souhami R

9

1 reference

13 May 2018

Urban N

10

1 reference

13 May 2018

Orsulic S

11

1 reference

13 May 2018

Smyth J

12

1 reference

13 May 2018

publication date

1 September 2003

1 reference

13 May 2018

European Journal of Cancer

published in

1 reference

13 May 2018

volume

39

1 reference

13 May 2018

issue

13

1 reference

13 May 2018

page(s)

1818-1827

1 reference

13 May 2018

Specific keynote: genome copy number abnormalities in ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Use of proteomic patterns in serum to identify ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Genetic analysis of benign ovarian tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

WWOX: a candidate tumor suppressor gene involved in multiple tumor types

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Development of a syngeneic mouse model for events related to ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Human ovarian surface epithelium in primary culture

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Induction of ovarian cancer by defined multiple genetic changes in a mouse model system

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

An RCAS-TVA-based approach to designer mouse models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Chemokine biology in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Osteopontin as a potential diagnostic biomarker for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Selecting Differentially Expressed Genes from Microarray Experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Combining several screening tests: optimality of the risk score

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900511-2

7 January 2021

10.1016/S0959-8049(03)00511-2

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018